Wedbush Reiterates Outperform Rating for TScan Therapeutics (NASDAQ:TCRX)

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating restated by analysts at Wedbush in a note issued to investors on Wednesday,RTT News reports. They presently have a $7.00 target price on the stock. Wedbush’s price target suggests a potential upside of 264.58% from the stock’s previous close.

TCRX has been the subject of several other reports. Needham & Company LLC cut their price objective on shares of TScan Therapeutics from $11.00 to $9.00 and set a “buy” rating for the company in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $15.00 target price on shares of TScan Therapeutics in a research note on Wednesday, December 11th.

TScan Therapeutics Stock Performance

Shares of TCRX stock traded down $0.10 on Wednesday, hitting $1.92. 309,208 shares of the stock were exchanged, compared to its average volume of 309,741. The firm’s 50 day moving average is $2.47 and its two-hundred day moving average is $4.07. TScan Therapeutics has a one year low of $1.82 and a one year high of $9.69. The firm has a market capitalization of $102.47 million, a PE ratio of -1.81 and a beta of 0.87. The company has a current ratio of 9.56, a quick ratio of 9.56 and a debt-to-equity ratio of 0.13.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Wednesday, March 5th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.02). TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. Sell-side analysts expect that TScan Therapeutics will post -1.12 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of TCRX. China Universal Asset Management Co. Ltd. bought a new stake in TScan Therapeutics during the fourth quarter valued at approximately $32,000. Prudential Financial Inc. purchased a new stake in shares of TScan Therapeutics during the 4th quarter valued at $32,000. ProShare Advisors LLC bought a new stake in shares of TScan Therapeutics during the 4th quarter worth $40,000. Wells Fargo & Company MN grew its position in TScan Therapeutics by 41.1% in the fourth quarter. Wells Fargo & Company MN now owns 19,540 shares of the company’s stock worth $59,000 after acquiring an additional 5,694 shares in the last quarter. Finally, Squarepoint Ops LLC purchased a new position in TScan Therapeutics in the fourth quarter worth $59,000. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.